Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 5/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL355415 | 1.00 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL76795 | 1.00 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL76796 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL29783468 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL196338 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL700933 | 0.98 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Methyl Alcohol SCHEMBL28477033 | 0.95 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Bromide SCHEMBL28031435 | 0.95 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Alcohol SCHEMBL28297686 | 0.94 | SLC7A5 (0.48) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL1532654 | 0.93 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025041931-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SARCOPENIA IN COMPANION ANIMALS | 마이오펫 주식회사 | 2025-02-27 | — | — | WO | claimed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| US-20220354817-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA CONTAINING NON-NATURAL AMINO ACID DERIVATIVE | MYO-TEC-SCI (KR) | 2022-11-10 | — | — | US | claimed |
| CN-115232130-A | APN and AKT double-target-point inhibitor and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114181116-A | D-amino acid derivative aminopeptidase N inhibitor and preparation method and application thereof | 山东中医药大学 | 2022-03-15 | — | — | CN | claimed |
| CN-112979485-A | Application of 3A type molecular sieve in synthesis of N- (4-acetylene benzene carbonyl) amino acid ester | 齐鲁工业大学 | 2021-06-18 | — | — | CN | claimed |
| US-12616732-B2 | Peptides for treatment of medical disorders | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-119836295-A | Peptides for the treatment of medical conditions | 人福医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025041931-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SARCOPENIA IN COMPANION ANIMALS | 마이오펫 주식회사 | 2025-02-27 | — | — | WO | disclosed |
| US-20240425450-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2024-12-26 | — | — | US | disclosed |
| EP-3398452-B1 | COMESTIBLE COMPOSITIONS COMPRISING HIGH POTENCY SAVORY FLAVORANTS | FIRMENICH INCORPORATED (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-112552374-B | Preparation method of peptide amide compound and intermediate thereof | 西藏海思科制药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| WO-1998008853-A9 | PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998008853-A1 | PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1997030027-A1 | BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-21 | — | — | WO | disclosed |
| US-4616002-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0145956-A1 | Composés amidés | CIBA-GEIGY AG (CH) | 1985-06-26 | — | — | EP | disclosed |
| EP-0038046-B1 | PHARMACEUTICAL AMIDES, AND PREPARATION, FORMULATIONS AND USE THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-29 | — | — | EP | disclosed |
| EP-0038046-A2 | Pharmaceutical amides, and preparation, formulations and use thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354817-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA CONTAINING NON-NATURAL AMINO ACID DERIVATIVE | TNNC1, MUSK, PYGM | SLC7A5 202/4885ANPEP 22/4885RNPEP 468/4885 |
| US-12616732-B2 | Peptides for treatment of medical disorders | OPRK1, OPRD1, OPRL1 | SLC7A5 1658/4885ANPEP 1311/4885RNPEP 1996/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | SLC7A5 3674/4885ANPEP 54/4885RNPEP 24/4885 |
| US-20240425450-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | SLC7A5 153/4885ANPEP 2134/4885RNPEP 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.